Charles River Laboratories International Inc. closed 46.74% short of its 52-week high of $264.71, which the company reached ...

This was the stock's second consecutive day of losses.

Corebridge Financial Inc. lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 5.5% during the fourth quarter, according to its most recent disclosure ...

Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to discover new molecules and potential therapies. Pfizer is partnering with ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Education has become a crucial factor for personal success and development in today’s world. Every year, there is an increasing demand for high-quality, affordable training that meets the needs of the ...

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...